Latest Insider Transactions at Johnson & Johnson (JNJ)
This section provides a real-time view of insider transactions for Johnson & Johnson (JNJ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of JOHNSON & JOHNSON to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of JOHNSON & JOHNSON's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Open market or private sale
|
Direct |
403
-2.6%
|
$62,868
$156.15 P/Share
|
|
Feb 18
2025
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
200
-0.22%
|
$31,200
$156.15 P/Share
|
|
Feb 18
2025
|
John C Reed EVP, Innovative Medicine, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
385
-2.42%
|
$60,060
$156.15 P/Share
|
|
Feb 18
2025
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
768
-12.56%
|
$119,808
$156.15 P/Share
|
|
Feb 18
2025
|
Kristen Mulholland EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-0.92%
|
$18,720
$156.15 P/Share
|
|
Feb 18
2025
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-0.84%
|
$21,996
$156.15 P/Share
|
|
Feb 18
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
651
-0.38%
|
$101,556
$156.15 P/Share
|
|
Feb 18
2025
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
94
-0.47%
|
$14,664
$156.15 P/Share
|
|
Feb 18
2025
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
1,602
-0.4%
|
$249,912
$156.15 P/Share
|
|
Feb 18
2025
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-2.97%
|
$47,892
$156.15 P/Share
|
|
Feb 18
2025
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.72%
|
$24,648
$156.15 P/Share
|
|
Feb 15
2025
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,029
+6.23%
|
-
|
|
Feb 15
2025
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
607
+0.66%
|
-
|
|
Feb 15
2025
|
John C Reed EVP, Innovative Medicine, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,350
+7.81%
|
-
|
|
Feb 15
2025
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,971
+24.38%
|
-
|
|
Feb 15
2025
|
Kristen Mulholland EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
419
+3.1%
|
-
|
|
Feb 15
2025
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
492
+2.85%
|
-
|
|
Feb 15
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
1,594
+0.92%
|
-
|
|
Feb 15
2025
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
339
+1.66%
|
-
|
|
Feb 15
2025
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
3,682
+0.92%
|
-
|
|
Feb 15
2025
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
961
+8.52%
|
-
|
|
Feb 15
2025
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
492
+2.2%
|
-
|
|
Feb 14
2025
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,847
-3.77%
|
$288,132
$156.23 P/Share
|
|
Feb 14
2025
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
4,571
+12.0%
|
-
|
|
Feb 14
2025
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,096
-1.08%
|
$482,976
$156.23 P/Share
|
|
Feb 14
2025
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,367
+3.67%
|
-
|
|
Feb 14
2025
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,312
-27.46%
|
$1,296,672
$156.23 P/Share
|
|
Feb 14
2025
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,330
+42.87%
|
-
|
|
Feb 14
2025
|
Kristen Mulholland EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
888
-2.18%
|
$138,528
$156.23 P/Share
|
|
Feb 14
2025
|
Kristen Mulholland EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,608
+8.55%
|
-
|
|
Feb 14
2025
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,599
-2.94%
|
$249,444
$156.23 P/Share
|
|
Feb 14
2025
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,079
+12.04%
|
-
|
|
Feb 14
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
9,669
-1.76%
|
$1,508,364
$156.23 P/Share
|
|
Feb 14
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
19,518
+5.0%
|
-
|
|
Feb 14
2025
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
730
-1.18%
|
$113,880
$156.23 P/Share
|
|
Feb 14
2025
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,201
+5.01%
|
-
|
|
Feb 14
2025
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
12,094
-0.99%
|
$1,886,664
$156.23 P/Share
|
|
Feb 14
2025
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
24,335
+2.85%
|
-
|
|
Feb 14
2025
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
946
-3.08%
|
$147,576
$156.23 P/Share
|
|
Feb 14
2025
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,203
+9.38%
|
-
|
|
Feb 14
2025
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
1,722
-2.47%
|
$268,632
$156.23 P/Share
|
|
Feb 14
2025
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
4,740
+9.14%
|
-
|
|
Feb 13
2025
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
499
+3.55%
|
-
|
|
Feb 13
2025
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+0.72%
|
-
|
|
Feb 13
2025
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,779
+50.0%
|
-
|
|
Feb 13
2025
|
Kristen Mulholland EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
411
+3.29%
|
-
|
|
Feb 13
2025
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
447
+2.89%
|
-
|
|
Feb 13
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
1,302
+0.77%
|
-
|
|
Feb 13
2025
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
312
+1.59%
|
-
|
|
Feb 13
2025
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
3,470
+0.88%
|
-
|